Comparing the current results to its competitors, Protagonist Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 3749.17 % year on year. The sales growth was above Protagonist Therapeutics Inc 's competitors' average revenue growth of 12.04 %, achieved in the same quarter.
Protagonist Therapeutics inc achieved net profit of $162.85 millions compared to a net loss of $-34.77 millions recorded in the same quarter a year ago.
Protagonist Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape includes emerging oral macrocyclic peptides such as PeptiDream’s dual IL-17A/IL-17F candidate. In the treatment of polycythemia vera (PV), competitors include Ruxolitinib (Jakafi®) marketed by Incyte, Besremi® (ropeginterferon alfa-2b-nicotinamide) by PharmaEssentia/AOP, bomedemstat by Merck/Imago, and givinostat by Italfarmaco. Additional competition arises from RNA-based therapies such as divesiran by Silence Therapeutics and DISC-3405 by Disc Medicine, as well as investigational therapies from Alnylam Pharmaceuticals and vamifeport by CSL Vifor. In obesity and weight management, competition is led by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, including approved injectable therapies Wegovy® (semaglutide) by Novo Nordisk and Zepbound® (tirzepatide) by Eli Lilly. The FDA approved oral Wegovy® by Novo Nordisk in December 2025. The landscape also includes multi-receptor agonists such as Retatrutide by Eli Lilly, CagriSema (a combination of semaglutide and cagrilintide) by Novo Nordisk, and MariTide (maridebart cafraglutide) by Amgen. Competitors named across filings include Alnylam Pharmaceuticals, Amgen, CSL Vifor, Disc Medicine, Eli Lilly, Incyte, Italfarmaco, Merck/Imago, Novo Nordisk, PeptiDream, PharmaEssentia/AOP, and Silence Therapeutics.
Due to outstanding performance in Overall company, revenue grew by 3749.17 % Protagonist Therapeutics inc improved its market share, to approximately 0.15 %.
Publicly Traded Peers of Protagonist Therapeutics inc
Verastem Inc Share Performance
-7.68%
Over The Past 5 Days
Verastem Inc
Profile
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Cadrenal Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies in the field of renal diseases.
Sources:
Protagonist Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Protagonist Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
